CHGCF (Chugai Pharmaceutical Co) Ending Cash Position: $-171 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHGCF Chugai Pharmaceutical Co Ltd CHGCF
85 GF Score
Price $42.29
GF Value $47.53
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Chugai Pharmaceutical Co Ending Cash Position?

Chugai Pharmaceutical Co CHGCF -2.06% 85 Ending Cash Position is $-171 Mil as of Jun. 2026. GuruFocus rates CHGCF with a GF Score™ of 85/100 and a GF Value™ of $47.53 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Chugai Pharmaceutical Co's Ending Cash Position for the quarter that ended in Jun. 2026 was $-171 Mil.

Chugai Pharmaceutical Co's quarterly Ending Cash Position increased from Dec. 2025 ($-191 Mil) to Mar. 2026 ($2,634 Mil) but then declined from Mar. 2026 ($2,634 Mil) to Jun. 2026 ($-171 Mil).

Chugai Pharmaceutical Co's annual Ending Cash Position increased from Dec. 2023 ($3,186 Mil) to Dec. 2024 ($3,512 Mil) but then declined from Dec. 2024 ($3,512 Mil) to Dec. 2025 ($2,736 Mil).

Chugai Pharmaceutical Co Ending Cash Position Related Terms

Chugai Pharmaceutical Co Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Chugai Pharmaceutical Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chugai Pharmaceutical Co Ending Cash Position Chart

Chugai Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,352.16 1,646.74 3,185.65 3,512.04 2,736.12

Chugai Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 509.88 -274.96 -191.32 2,634.09 -171.33
CHGCF
85GF Score
Chugai Pharmaceutical Co Ltd CHGCF
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chugai Pharmaceutical Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Chugai Pharmaceutical Co's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=3464.721+-728.602
=2,736

Chugai Pharmaceutical Co's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=1.4210854715202E-13+-171.332
=-171

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $-171 Mil mean?
Chugai Pharmaceutical Co (CHGCF) has a Ending Cash Position of $-171 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Chugai Pharmaceutical Co and its competitors.
Is Chugai Pharmaceutical Co's Ending Cash Position too high?
Chugai Pharmaceutical Co's current Ending Cash Position is $-171 Mil. Overall, Chugai Pharmaceutical Co has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's Ending Cash Position compare to LLY and JNJ?
Chugai Pharmaceutical Co's Ending Cash Position of $-171 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Chugai Pharmaceutical Co and its competitors. Chugai Pharmaceutical Co's current Ending Cash Position is $-171 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co (CHGCF) is currently considered Modestly Undervalued. The stock's GF Value™ is $47.53, compared to a current price of $42.29 — trading 11% below its estimated fair value. The current Ending Cash Position is $-171 Mil. Chugai Pharmaceutical Co's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Chugai Pharmaceutical Co (CHGCF), the current Ending Cash Position is $-171 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chugai Pharmaceutical Co (CHGCF) Overvalued in 2026?

Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued. The current stock price of $42.29 is trading 11% below its estimated GF Value™ of $47.53. GuruFocus considers Chugai Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for CHGCF:

  • Ending Cash Position: $-171 Mil
  • GF Value™: $47.53 vs. price of $42.29 (11% below fair value)
  • GF Score™: 85/100 with 1 warning sign

No single metric tells the full story. See the CHGCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chugai Pharmaceutical Co Business Description

Address 2-1-1 Muromachi, Nihonbashi, 12th Floor, Nihonbashi Mitsui Tower, Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
85GF Score

Get the complete analysis for CHGCF

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$42.29
Price
$47.53
GF Value